Article published Sep 28, 2026. Prices below use latest available snapshots.
IQV Price Structure
Loading timeframes…
$IQV is doing well: up 40.2% since June 29 and up 3.5% since August 28, 32.2% above its 200-day average, and up 49.9% over the past year. At the 2026-09-28 settled close, IQV $270.97 was +1.8% versus its 20-day average and +3.5% over 30 days. The newest verified quarter ends 2026-06-30 (filed 2026-07-28); revenue was $4.37B. Against 2025-06-30 revenue of $4.02B, that is +8.7% year over year. The stock re-rated sharply on the July print, so November bookings and trial starts must support the price; the September 28 news check did not complete. The standing call is 🟡 Buy the breakout, not the middle. Entry $274–$282 on a close above the base pivot · stop $252 · first target $300 · medium conviction.
Quick Snapshot (as of 2026-09-28)
| Question | Answer |
|---|---|
| The call | 🟡 Buy the breakout, not the middle. Entry $274–$282 on a close above the base pivot · stop $252 · first target $300 · medium conviction. |
| What it is | The largest contract research and healthcare-data company: clinical-trial services for drug developers plus data, analytics and technology for life-sciences commercial teams. |
| Why now | Prior case (2026-09-23): Biotech funding and trial starts drive its research business, and the stock re-rated on its July print. |
| Proof | Latest verified period ended 2026-06-30, filed 2026-07-28: revenue $4.37B. Prior case: The stock rose 16.1% across the July 28 report, per the desk's earnings record; the move has held for two months. |
| Objection | The stock re-rated sharply on the July print, so November bookings and trial starts must support the price; the September 28 news check did not complete. |
| Stock setup | The long trend remains intact; +1.8% versus the 20-day, +32.2% versus the 200-day, RSI 61.1. |
Action Matrix (reviewed 2026-09-28; levels are standing conditions)
| Signal | If | Then |
|---|---|---|
| 🟢 Buy | A daily close above $273.88, the base pivot | Entry $274–$282; the base breaks in the direction of the trend. |
| 🟡 Wait | Price stays inside the base | No edge in the middle; a pullback to the 50-day (about $245) would be the other acceptable entry. |
| 🔴 Out | After an entry, a close below $252 | The breakout failed back into the base. |
| 🟠 Target | $300 | First target; trail beyond it. |
| 🔴 Thesis breaks | The November 3 report shows bookings or trial starts slowing | The biotech-funding recovery is not reaching the research pipeline. |
The Story Right Now (as of 2026-09-28)
$IQV is doing well: up 40.2% since June 29 and up 3.5% since August 28, 32.2% above its 200-day average, and up 49.9% over the past year.
Data as of 2026-09-28 close: IQV $270.97, RSI 61.1, strong-up, +1.8% vs SMA20, +32.2% vs SMA200, 7D +0.4%, 30D +3.5%, 1Y +49.9%, -2.3% from the 52-week high.
Business and mechanism. The largest contract research and healthcare-data company: clinical-trial services for drug developers plus data, analytics and technology for life-sciences commercial teams.
Prior case (2026-09-23). Biotech funding and trial starts drive its research business, and the stock re-rated on its July print.
Prior proof (2026-09-23). The stock rose 16.1% across the July 28 report, per the desk's earnings record; the move has held for two months.
The countercase. The stock re-rated sharply on the July print, so November bookings and trial starts must support the price; the September 28 news check did not complete.
Newest statement check. The newest verified quarter ends 2026-06-30 (filed 2026-07-28); revenue was $4.37B. Against 2025-06-30 revenue of $4.02B, that is +8.7% year over year.
News and attention check. The news search for the latest move failed; the last completed search was on 2026-09-25. No company event for IQV was recorded between September 24 and 28.
The call: 🟡 Buy the breakout, not the middle. Entry $274–$282 on a close above the base pivot · stop $252 · first target $300 · medium conviction.
Extended analysis
Price Data (live)
Live values from the desk's settled-close summaries. They update with each close; the dated sections above keep the numbers of their own date.
| Metric | IQV |
|---|---|
| As of (close) | 2026-10-16 |
| Price ($) | 266.9 |
| RSI (14) | 54.8 |
| vs SMA20 (%) | 0.6 |
| vs SMA50 (%) | 2.6 |
| vs SMA200 (%) | 28.5 |
| SMA20 ($) | 265.34 |
| SMA50 ($) | 260.02 |
| SMA200 ($) | 207.74 |
| 1D (%) | -1.53 |
| 7D (%) | 2.7 |
| 30D (%) | -0.71 |
| 3M (%) | 29.4 |
| 1Y (%) | 29.72 |
| 2Y (%) | 14.52 |
| 1Y vs S&P 500 (pts) | 14.19 |
| From 52-week high (%) | -3.79 |
Financial Proof
Filed-period check (as of 2026-09-28): The newest verified quarter ended 2026-06-30 and was filed 2026-07-28. Revenue was $4.37B; GAAP net income was $258.0M; diluted EPS was 1.53. Source: Massive income statements and the filing. Dated historical tables below retain their own period basis.
The recent filed revenue series shows the direction of the business; missing cells are left unavailable.
| Period end | Revenue | YoY | Operating income | GAAP net income | Filing date |
|---|---|---|---|---|---|
| 2024-09-30 | $3.90B | — | $550.0M | $285.0M | 2024-10-31 |
| 2025-03-31 | $3.83B | — | $496.0M | $249.0M | 2025-05-06 |
| 2025-06-30 | $4.02B | — | $506.0M | $266.0M | 2025-07-22 |
| 2025-09-30 | $4.10B | +5.2% | $553.0M | $332.0M | 2025-10-28 |
| 2026-03-31 | $4.15B | +8.4% | $514.0M | $275.0M | 2026-05-05 |
| 2026-06-30 | $4.37B | +8.7% | $506.0M | $258.0M | 2026-07-28 |
Research Log
| Date | Note |
|---|---|
| 2026-04-10 | Initial deep dive. IQV $165.65, RSI 41.6, strong-down. Death cross. |
| 2026-05-29 | IQV $182.21, RSI 61.8, weak-up; +15.05% 30D. Trend reversing. No new fundamentals re-researched. |
| 2026-06-16 | IQV $179.17, RSI 52, neutral; -6.15% 7D, +3.68% 30D. 7D pullback from May 29; price back at SMA20. Recovery trend intact but consolidating. SMA20 hold is the key tell. No new fundamentals re-researched. |
| 2026-07-11 | IQV $207.85, RSI 68.3, up; +16.0% since 06-16. SMA20-hold scenario confirmed and accelerated — 30D +14.8%, 3M +20.85%. RSI approaching overbought — new watch item. No new fundamentals re-researched. |
| 2026-07-17 | IQV $206.26, RSI 62.4, up; -0.8% since 07/11, +22.94% 30D (still accelerating), +16.69% 3M. RSI cooled off the near-overbought read, a healthy reset rather than a reversal. No new fundamentals re-researched. |
| 2026-07-25 | IQV $208.05, RSI 61.6, up; +0.9% since 07/17, +12.08% 30D (moderated), +28.2% 3M (accelerated). Consolidating above all major MAs. No new fundamentals re-researched. |
| 2026-07-28 | IQV $242.94, RSI 79.1, up (regime: parabolic); +16.8% since 07/25 (+13.94% single day), +25.69% 30D, +55.07% 3M. -1.93% from 52wk high, near new highs. RSI now overbought. no news identified Correction 2026-08-03: the +13.94% day was IQV's July 28 earnings reaction (+16.1% across the print, per its calendar event) — not an unexplained extension. No new fundamentals re-researched. |
| 2026-07-31 | IQV $235.02, RSI 68.2, up; 7D +12.96%; 30D +15.66%; 3M +48.96%; -6.50% from 52wk high. No new fundamentals re-researched. |
| 2026-08-08 | IQV $238.70, RSI 65.5, strong-up; 7D +1.57%; 30D +17.13%; 3M +33.57%; -6.09% from 52wk high. No new fundamentals re-researched. |
| 2026-08-14 | IQV $236.66, RSI 61.6, strong-up; 7D -0.85%; 30D +14.43%; 3M +39.94%; -3.91% from 52wk high. No new fundamentals re-researched. |
| 2026-08-22 | IQV $259.82, RSI 72.6, strong-up; 7D +9.81%; 30D +30.88%; 3M +54.75%; -0.22% from 52wk high. 1Y +40.15%, vs SMA200 +30.20%. No new fundamentals re-researched. |
| 2026-08-28 | IQV $261.75, RSI 72.4, strong-up; 7D +0.70%; 30D +5.73%; 3M +43.65%; -1.32% from 52wk high. 1Y +38.69%, vs SMA200 +30.4%. No new fundamentals re-researched. |
| 2026-09-04 | IQV $267.77, RSI 69.6, strong-up; 7D +2.30%; 30D +13.44%; 3M +45.96%; -1.48% from 52wk high. 1Y +45.46%, vs SMA200 +32.60%. News not pulled for this move (last fetched 2026-06-21, well before this window). |
| 2026-09-11 | IQV $261.77, RSI 60.7, strong-up; 7D -2.24%; 30D +8.30%; 3M +44.26%; -3.69% from 52wk high. 1Y +37.28%, vs SMA200 +29.20% — still a deep pullback in an intact trend. Stock-events checked, none on file. News not pulled for this move (cache still last fetched 2026-06-21). No new fundamentals filed since 09-04. |
| 2026-09-18 | IQV $266.42, RSI 61.5, strong-up; 7D +1.78%; 30D +6.88%; 3M +58.80%; -2.72% from 52wk high. 1Y +40.07%, vs SMA200 +30.8% — an intact long trend near its high. Friday traded at 4.04x normal volume on quarterly expiry. News not pulled for this move (receipt last written 2026-06-21, nearly three months stale). Stock-events checked: none in this window. No newly filed period on disk this cycle; the newest filed quarter is 2026 Q1. |
| 2026-09-23 | IQV $267.86, RSI 61.1, +1.2% vs SMA20, 30D +2.93%. Basing 3.44% under the high (7.8-week base, pivot $273.88); 1Y +43.66%, 1Y vs S&P 500 +27.89 pts, +31.1% vs the 200-day — intact trend in a flag. Call set to a breakout entry above the pivot. News not pulled for this move (receipt last written 2026-06-21). Stock-events checked: none in the window; Q3 report 11-03. Filed-period check: Q1 2026 newest on disk; Q2 10-Q not on disk and not cited. |
| 2026-09-28 | IQV $270.97, RSI 61.1, +1.8% vs SMA20, 30D +3.5%. The long trend remains intact; The newest verified quarter ends 2026-06-30 (filed 2026-07-28); revenue was $4.37B. Against 2025-06-30 revenue of $4.02B, that is +8.7% year over year. The news search for the latest move failed; the last completed search was on 2026-09-25. No company event for IQV was recorded between September 24 and 28. |
Sources
- News receipt: latest (last written 2026-06-21).
- Scheduled-event check: 2026-11-03-iqv-earnings (scheduled); no IQV row dated 2026-09-19 to 2026-09-23.
- Macro: CNBC, Fed delivers its first hike in three years (2026-09-16); Bloomberg, US bond-market slide deepens (2026-09-23); Bloomberg, biggest long-bond ETF hits record low (2026-09-23); CNBC, market sees next Fed hike in October (2026-09-23).
- market-pulse — sector-fund and S&P 500 30-day returns, September 23, 2026.
2026-09-28 refresh receipts
2026-09-28 settled-close receipt: *, IQV row dated 2026-09-28; tape values above are bound to the current summary fields.
2026-09-28 financial-period check: income-statements and key-financials; newest verified 2026-06-30 period, filed 2026-07-28 (Massive statement / SEC period cross-check).
2026-09-28 news receipt check: latest, fetched 2026-09-25; receipt is not current; latest-session cause remains unassigned.
2026-09-28 stock-event scan:
research/stock-events/, no IQV row dated 2026-09-24 through 2026-09-28.2026-09-28 captured-follows scan: tweets has 0 September 24–28 document(s) tagging IQV.
Retrospective social-search receipt (captured 2026-09-29): 2026-09-29-social-search-iqv; quality/attention check only, not a September 28 event or price source.
2026-09-29 browser discovery check for IQV: news-discovery-google-sep29 (key
IQV); search links only, not evidence of an event or of absence of news.